Tests revealed the ability to generate immunity in both young adults and the elderly. Risk groups will be the first to be vaccinated with licenses for emergency cases, reveals the British newspaper Independent
The vaccine that is being developed by the University of Oxford could be validated and authorized before the end of the year, reports the English newspaper Independent today.
According to the same report, the data experienced so far reveal that this potential vaccine generates similar immunities in young and old, according to information from AstraZeneca, a pharmaceutical company involved in the study and testing.
Immunogenicity tests – the ability of a substance to trigger an immune response in the body – carried out on a group of older study participants revealed that the vaccine activates protective antibodies and T cells among the elderly – one of the highest risk age groups with regard to to Covid-19.
“It is encouraging to see that immunogenicity responses were similar between older and younger adults, and that and that the reactogenicity (adverse or side reaction) was lower among older adults, where the severity of disease 19 is greatest,” said one AstraZeneca spokesman to Reuters news agency.
“The results [mais recentes do estudo] reinforce evidence of the safety and immunogenicity of AZD1222, “added the spokesman, referring to the technical name of the vaccine tested at Oxford.
However, says the Independent, despite these motivating results and the fact that older people may develop immunity with the vaccine, this does not guarantee that it is already in a state of development that guarantees safety and effectiveness. In other words, this risk group needs to verify more analyzes.
The Oxford vaccine, which will be produced by AstraZeneca, is among the most advanced candidates, all of which are still in the development stage, namely those from Pfizer and Moderna laboratories.
However, Adrian Hill, the chief investigator for the Oxford program, said that doctors and high-risk patients could receive doses of AZD1222 before the end of 2020. “The first licenses will be for emergency use, they will not have approval widespread, “he told several members and alumni of Oxford’s Magdalen College, one of the prestigious university’s colleges. According to Hill, regulators “will want to see more data on safety and effectiveness before granting a license to vaccinate everyone.”
The University of Oxford and AstraZeneca are conducting tests at nine sites in Britain, involving 10,000 volunteers. Other tests are being carried out in Brazil, South Africa, India and the United States.
– .
